X4 Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a XFOR research report →
Range $11 – $12
Price Chart
About the company
X4 Pharmaceuticals, Inc. is a biopharmaceutical firm committed to the discovery, development, and commercialization of innovative therapies for uncommon immune system disorders. Its primary drug candidate, XOLREMDI (also known as mavorixafor), is an orally administered, small-molecule antagonist specifically designed to target the chemokine receptor CXCR4.
- CEO
- Adam R. Craig
- IPO
- 2017
- Employees
- 45
- HQ
- Boston, MA, US
Get TickerSpark's AI analysis on XFOR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $306.34M
- P/E
- -4.44
- Fwd P/E
- 2.52
- PEG
- -0.02
- P/S
- 17.89
- P/B
- 2.71
- EV/EBITDA
- -2.78
- Div Yield
- 0.00%
- Gross Margin
- 81.63%
- Op Margin
- -473.95%
- Net Margin
- -474.74%
- ROE
- -49.62%
- ROIC
- -37.04%
Latest fiscal year · YoY change
- Revenue
- $35.11M+1273.2%
- Gross Profit
- $28.86M+1539.5%
- Op Income
- $-86,883,000
- Net Income
- $-79,199,000-111.5%
- EPS
- $-1.87+66.5%
- OCF Growth
- +34.6%
- FCF Growth
- +35.9%
- 52W High
- $4.83
- 52W Low
- $2.43
- 50D MA
- $3.10
- 200D MA
- $3.76
- Beta
- 0.35
- RSI (14)
- 44
- Avg Volume
- 868.24K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
X4 reported a small first-quarter commercial contribution from XOLREMDI while advancing its larger chronic neutropenia program, with enrollment on track for a pivotal Phase 3 readout in the second half of 2026.· May 1, 2025
- 4WARD, the Phase 3 chronic neutropenia trial, is now enrolling in over 20 countries with more than 90% of target sites activated.
- Management said the trial was refined with FDA/EMA feedback to focus on moderate-to-severe patients with recurrent infections, and enrollment demographics look balanced so far.
- XOLREMDI first-quarter net revenue was just under $1 million, and cumulative sales since the mid-May launch reached $3.5 million.
- The company ended Q1 with just under $90 million in cash and said its restructuring should reduce annual spending by $30 million to $35 million.
- X4 received a U.S. notice of allowance for CN patent claims expiring in March 2041, and its Norgine deal covers both WHIM and CN in Europe, Australia, and New Zealand.
X4 ended the first quarter of 2025 with just under $90 million in cash and cash equivalents, and management said that is expected to fund operations into the first half of 2026. Net XOLREMDI revenue for Q1 2025 was just under $1 million, bringing cumulative sales since the mid-May 2024 launch to about $3.5 million. R&D expense was $18.5 million and SG&A was $15 million. The company reported a small net income in Q1, helped by $28 million of license and other revenue from the Norgine partnership and a $10.8 million gain on Class C warrants. Forward-looking, X4 still expects full enrollment in the 4WARD CN trial in the third or fourth quarter of 2025, which would support top-line data in the second half of 2026.
Paula Ragan framed Q1 as a productive quarter focused on advancing mavorixafor in both chronic neutropenia and WHIM syndrome. She emphasized that the CN program is being positioned around the highest-unmet-need patients and highlighted new heat-map analyses from prior studies as reinforcing confidence in Phase 3 success. Her tone was upbeat and conviction-oriented, especially around the size of the CN opportunity and the durability of the patent position.
Adam Mostafa highlighted just under $90 million in cash at quarter-end and reiterated guidance that this should support operations into the first half of 2026. He pointed to Q1 R&D of $18.5 million and SG&A of $15 million, then noted the quarter’s small net income was driven by $28 million of license and other revenue from Norgine plus a $10.8 million warrant gain. He also said the February restructuring actions are largely complete and should cut annual spending by $30 million to $35 million, and he noted the 1-for-30 reverse split became effective to address the NASDAQ listing deficiency.
Analysts focused on who is being enrolled in 4WARD, whether the eventual CN label could be broad or limited to the very sick subgroup, and whether commercial WHIM patients are adhering to therapy. Management said the enrolled CN patients look like the intended high-unmet-need population, with balanced idiopathic, autoimmune, and congenital representation, and said they are seeing event rates early in the blinded study that support the trial assumptions. On labeling, management said they are building a case for the broader CN population but expect FDA discussions to matter. In WHIM, they said adherence/compliance looks better than expected for a daily oral drug and that most prescriptions are currently for a one-month supply.
The bull case is that X4 appears to be executing on a pivotal CN program that management believes is well powered, on track, and aimed at a large, high-unmet-need population. They also pointed to early commercial traction in WHIM, expanding physician awareness, new patient growth, and global partnership progress with Norgine and taiba rare.
The bear case is that WHIM commercialization is still very small, with quarterly revenue just under $1 million and sales described as lumpy because of inventory timing in a tiny market. The CN story is still clinical-stage, so the value depends on a Phase 3 readout in 2026, and management acknowledged that the eventual label will depend on FDA discussions. Cash is also finite, even after the restructuring, with funding expected only into the first half of 2026.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 59.0%
- Shares Outstanding
- 102.11M
- Float Shares
- 60.23M
of shares held by institutions
91 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Morgan Stanley | 11.00M | ▲ 1.53M |
| Empery Asset Management, LP | 9.73M | ▲ 2.79M |
| Bain Capital Life Sciences Investors, LLC | 7.97M | 0 |
| Venrock Adviser, LLC | 7.64M | ▲ 5.71M |
| Saturn V Capital Management LP | 7.37M | ▲ 393.10K |
| Perceptive Advisors LLC | 7.35M | ▼ 583.00K |
| Blackrock, Inc. | 5.85M | ▲ 299.62K |
| Fmr LLC | 5.49M | ▼ 2.83M |
| Deep Track Capital, LP | 4.50M | ▼ 1.38M |
| Kalehua Capital Management LLC | 3.72M | 0 |
| Vanguard Capital Management LLC | 3.56M | ▼ 157.27K |
| Vanguard Group Inc | 3.42M | ▲ 3.01M |
Held by 105 ETFs
Biggest fund positions in XFOR by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 16, 26 | Craig Adam R | buy | 4,600 |
| Oct 1, 26 | KIRSKE DAVID | sell | 11,767 |
| Aug 12, 26 | Volpone John | sell | 24,576 |
| Aug 12, 26 | Craig Adam R | sell | 47,436 |
| Jun 30, 26 | KIRSKE DAVID | sell | 8,543 |
| Jul 1, 26 | Gold Kelly | other | 110,000 |
| Jul 1, 26 | Gold Kelly | other | 0 |
| May 12, 26 | KIRSKE DAVID | sell | 16,961 |
| Jan 1, 26 | Bridger Gary | other | 110,000 |
| Jan 1, 26 | de Craecker Francoise | other | 110,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our XFOR coverage
Recent articles, reports, and earnings notes.
No research on XFOR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate XFOR report →X4 Pharmaceuticals (XFOR) Reports Q3 Loss, Tops Revenue Estimates
zacks.com · Nov 4
X4 Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com · Nov 4
X4 Pharmaceuticals to Participate in Guggenheim, Stifel, and Jefferies Conferences in November 2026
globenewswire.com · Nov 3
4 Biotech Stocks Seeing Unusual Options Volume Today
schaeffersresearch.com · Nov 3
X4 Pharmaceuticals, Inc. (XFOR) Analyst/Investor Day Transcript
seekingalpha.com · Oct 30
X4 Pharmaceuticals Highlights Clinical Progress and Market Opportunity for Mavorixafor in Primary Chronic Neutropenia During Virtual Investor Day
globenewswire.com · Oct 29
X4 Pharmaceuticals Targets 2028 Phase III Data for Mavorixafor in Chronic Neutropenia
marketbeat.com · Oct 29
Head to Head Review: Entrada Therapeutics (NASDAQ:TRDA) versus X4 Pharmaceuticals (NASDAQ:XFOR)
defenseworld.net · Oct 22
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.